Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 11/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11029026 | 0.87 | HDAC6 (0.77) | HDAC6HDAC8HDAC1ROCK2CA12 | |
| SCHEMBL11891361 | 0.86 | HDAC6 (0.80) | HDAC6HDAC8HDAC1FPR2CA12 | |
| SCHEMBL11027466 | 0.85 | HDAC6 (1.00) | HDAC6HDAC8HDAC1CA12CA1 | |
| SCHEMBL11031949 | 0.85 | HDAC6 (0.79) | HDAC6HDAC8HDAC1FPR2CA12 | |
| SCHEMBL11891202 | 0.85 | HDAC6 (1.00) | HDAC6HDAC8HDAC1FPR2CA12 | |
| SCHEMBL11026283 | 0.83 | HDAC6 (1.00) | HDAC6HDAC8HDAC1FPR2CA12 | |
| SCHEMBL11031776 | 0.83 | HDAC6 (0.80) | HDAC6HDAC8HDAC1CA12CA1 | |
| SCHEMBL11029934 | 0.82 | HDAC6 (0.78) | HDAC6HDAC8HDAC1CA12CA1 | |
| SCHEMBL11030802 | 0.81 | HDAC6 (1.00) | HDAC6HDAC8HDAC1ROCK2FPR2 | |
| SCHEMBL11030022 | 0.81 | HDAC6 (0.83) | HDAC6HDAC8HDAC1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665706-B1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | claimed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | claimed |
| EP-2665706-B1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2665706-B1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2665706-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012098132-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HRH4, H1-4, HNMT | HDAC6 155/4885HDAC8 107/4885HDAC1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.